OncoMatch/Clinical Trials/NCT03259867
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Is NCT03259867 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab Injectable Product and Trans-arterial tirapazamine embolization for hepatocellular carcinoma.
Treatment: Nivolumab Injectable Product · Trans-arterial tirapazamine embolization — This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Gastric Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced HCC or metastatic gastric cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: immune therapy — advanced HCC
HCC patients...should have progressive disease (PD) on an immune therapy for advanced HCC
Must have received: systemic chemotherapy — metastatic gastric cancer
patients with metastatic gastric cancer...should have failed at least one line of systemic chemotherapy
Must have received: immune checkpoint inhibitor — metastatic gastric cancer
patients with metastatic gastric cancer...should have failed at least one line of...an immune checkpoint inhibitor
Lab requirements
Blood counts
Hgb >= 8, platelet >= 50,000
Kidney function
Cr <= 2
Liver function
AST and ALT < 10 X ULN, t-Bilirubin < 3, Child-Pugh scores 5-7 for HCC patients
Hgb>=8, platelet >= 50,000, Cr =< 2, AST and ALT < 10 X ULN, t-Bilirubin < 3, Child-Pugh scores 5-7 for HCC patients
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine · Orange, California
- University of Oklahoma Health Science Center · Oklahoma City, Oklahoma
- Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03259867 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immune therapy and systemic chemotherapy.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages